Evidence map›Paper›PMID 31660303›Full record

ReviewAnnals of translational medicine2019

The dilemma of aspirin resistance in obese patients.

Devarshi Ardeshna, Sarthak Khare, Pooja S Jagadish, Venugopal Bhattad, Brandon Cave, Rami N Khouzam

Open access · diamondAbstract readReview
In one paragraph

Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Devarshi ArdeshnaCollege of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Sarthak KhareDepartment of Medicine, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA.
Pooja S JagadishDepartment of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Venugopal BhattadDepartment of Cardiovascular Diseases, East Tennessee State University, Johnson City, TN, USA.
Brandon CaveDepartment of Pharmacy, Methodist University Hospital, Memphis, TN, USA.
Rami N KhouzamDivision of Cardiovascular Diseases, Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
University of Tennessee Health Science Center · USEast Tennessee State University · USMethodist University Hospital · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspirin resistance (AR) commonly refers to the concept of reduced aspirin efficacy in preventing cardiovascular disease and platelet inhibition. Obesity increases the risk of heart disease three- to four-fold and has been associated with AR. Aspirin is used as a tool for both primary and secondary prevention, but recent studies suggest that its lack of efficacy for primary prevention is partly attributable to obesity. Several mechanisms have been described that contribute to AR in obese patients using pharmacokinetics and pharmacodynamics. AR may be attenuated through weight loss, alternative dosing regimens, and different drug formulations. With the global rise of obesity, it is imperative to find preventive therapies that adequately address atherosclerotic cardiovascular disease (ASCVD) risk in this population.

Indexed as

aspirinAspirin resistance (AR)obesity

Identifiers

PMID31660303
PMCPMC6787378
OpenAlexW2967432951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.